Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations

PharmacoEconomics

Volumn 22, Issue 12, 2004, Pages 759-769

  Nuijten, Mark J C ^a  

^a MEDTAP International   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; DRUG;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; HYPOTHESIS; MATHEMATICAL MODEL; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; REIMBURSEMENT; RESPONSIBILITY; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; UNCERTAINTY;

ANTIPARKINSON AGENTS; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS; COHORT STUDIES; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; MODELS, ECONOMIC; MONTE CARLO METHOD; PARKINSON DISEASE; QUALITY-ADJUSTED LIFE YEARS; UNCERTAINTY;

EID: 4344683138     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422120-00001     Document Type: Review

References (15)

1. Nuijten MJC, Berto P, Berdeaux G, et al. Trends in decision-making process for pharmaceuticals in Western European countries: a focus on emerging hurdles for obtaining reimbursement and a price. HEPAC 2 2001; 4: 162-9
2. Robinson R. Economic evaluation and health care: what does it mean? BMJ 1993; 307: 670-3
3. Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomised controlled trials. Med Care 1992; 30 (3): 231-43
4. Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Im J Technol Assess Health Care 1991; 7 (4): 561-73
5. Drummond MF, Ludbrook A, Lowson K, et al. Studies in economic appraisal in health care. Oxford, Oxford University Press 1986; 2
6. Clemens K, Townsend R, Luscombe F, et al. Methodological and conduct principles for pharmacoeconomic research. Pharmacoeconomics 1995; 8 (2): 169-74
7. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-83
8. Jefferson T, Demichelli V. Are guidelines for peer-reviewing economic evaluation necessary?. A survey of current editorial practice. Health Econ 1995; 4: 383-8
9. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997 May-Jun; 6 (3): 217-27
10. Nuijten MJC. Measuring sensitivity in pharmacoeconomic studies: refining point sensitivity and range sensitivity by incorporating probability distributions. Pharmacoeconomics 1999; 16 (1): 33-41
11. Nuijten MJC. Bridging decision analytic modelling with a cross-sectional approach: application to Parkinson's disease. Pharmacoeconomics 2000 Mar; 17 (3): 227-36
12. Nuijten MJ, van Iperen P, Palmer C, et al. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health 2001 Jul-Aug; 4 (4): 316-28
13. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985; 5 (2): 157-77
14. Parmigiani G. Measuring uncertainty in complex decision analysis models. Stat Methods Med Res 2002 Dec; 11 (6): 513-37
15. Cooper NJ, Sutton AJ, Abrams KR. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section. Stat Methods Med Res 2002 Dec; 11 (6): 491-512